DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Coverage details, prior authorization criteria, copay ranges, and appeal strategy for 2026. Verified May 1, 2026.
Largest US commercial insurer. Strict PA across all GLP-1s — BMI ≥30 (or ≥27 with comorbidity) + 12-month documented diet/exercise + step therapy through phentermine OR orlistat in most plans.
UnitedHealthcare requires the following before approving Wegovy:
Top denial patterns we see in 2026 based on appeal-claim data:
UHC strictest of major insurers — 12-month lifestyle is non-negotiable. If denied, OptumRx peer-to-peer review (provider calls medical director) has highest reversal rate.
OptumRx PA appeal → submit through provider portal → 30-day standard, 72h expedited.
Wegovy (semaglutide 2.4mg) carries the following FDA-approved indications. Off-label use is the #1 PA denial reason — ensure your prescribing diagnosis matches one of these.
Coverage details verified May 1, 2026 against UnitedHealthcare formulary documentation. Formulary changes happen quarterly — always verify against your specific plan before prescribing.